Your browser doesn't support javascript.
loading
circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway.
Shou, Yi; Yue, Changjie; Wang, Qi; Liu, Jingchong; Xu, Jiaju; Miao, Qi; Liu, Di; Yang, Hongmei; Liu, Yuenan; Zhang, Xiaoping.
Afiliación
  • Shou Y; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Yue C; Institute of Urologic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Wang Q; Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
  • Liu J; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Xu J; Institute of Urologic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Miao Q; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Liu D; Institute of Urologic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Yang H; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Liu Y; Institute of Urologic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Zhang X; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Cell Death Dis ; 14(3): 232, 2023 03 31.
Article en En | MEDLINE | ID: mdl-37002206
Renal cell carcinoma (RCC) is characterized by the difficulties in early diagnosis and the propensity to metastases. For advanced RCC, sunitinib targeted therapy is the clinically recommended first-line drug and the major challenge of sunitinib treatment is adaptive resistance. Therefore, it is imperative to research the mechanisms underlying sunitinib resistance. In this study, we discovered that circPTPN12 was highly expressed in RCC tissues and was associated with poorer clinical outcomes. circPTPN12 could promote the proliferation, migration, invasion, and sunitinib resistance of RCC cells. Mechanistically, circPTPN12 was found to form a complex with hnRNPM, which was involved in the regulation of mRNA processing. The combination with circPTPN12 enhanced the ability of hnRNPM to maintain the stability of IL-6 mRNA and further activated the STAT3 signaling pathway. The study revealed that circPTPN12/hnRNPM/IL-6/STAT3 axis promoted RCC progression and sunitinib resistance, which might be a promising therapeutic target for relieving sunitinib resistance in RCC.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Screening_studies Límite: Humans Idioma: En Revista: Cell Death Dis Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Screening_studies Límite: Humans Idioma: En Revista: Cell Death Dis Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido